Biotech News Alert: GenSpera (OTCQB:GNSZ) Announces US Patent
for Methods and Compositions for the Detection, Imaging and Treatment of Cancer
SAN ANTONIO - July 30, 2014 (Investorideas.com Biotech
Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for
the treatment of cancer, announces the issuance of a United States patent
entitled "Methods and compositions for the detection of cancer". The
patent US 8,772,226 B2 was issued July 8, 2014.
The
patent contains composition claims for thapsigargin-containing prodrugs that
can be radiolabelled and then activated by the enzymes Prostate Specific
Membrane Antigen (PSMA), Prostate Specific Antigen (PSA) or Human Glandular
Kallikrein 2 (hK2). The patent also claims methods of using such radiolabelled
prodrugs for the detection, imaging and treatment of cancers in humans.
The co-inventors on the patent include Drs.
Samuel Denmeade, John Isaacs and Soren Brogger Christensen who are all members
of GenSpera's Scientific Advisory Board.
"As we evaluate G-202 further in the
liver cancer and glioblastoma Phase II clinical trials it is clear that the
technology described in this patent, when fully developed, would greatly aid in
the selection of patients most likely to benefit from G-202 treatment,"
said Craig Dionne, PhD, GenSpera's CEO. "The issuance of this patent also
exemplifies the breadth and diversity of GenSpera's intellectual property
portfolio."
Read this release
in full at http://www.investorideas.com/CO/GNSZ/news/2014/07301.asp
About GenSpera
GenSpera's technology platform combines a
powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system
that provides for the targeted release of drug candidates within a tumor.
Unlike typical chemotherapeutic agents, thapsigargin results in cell death
irrespective of the rate of cell division, which may provide an effective
approach to kill both fast- and slow-growing cancers. GenSpera's lead drug
candidate, G-202, is activated by the enzyme PSMA, which is found at high
levels in the vasculature of liver and glioblastoma cancers and in the
vasculature of almost all other solid tumors. G-202 is therefore expected to
have potential efficacy in a wide variety of tumor types.
G-202 Phase II clinical trials are underway
in both hepatocellular carcinoma and glioblastoma patients.
For more information, please visit the
company's website: www.genspera.com or follow us on
Twitter @GenSperaNews.
Cautionary Statement Regarding Forward Looking Information
This news release may contain
forward-looking statements. Investors are cautioned that statements in this
press release regarding potential applications of GenSpera's technologies
constitute forward-looking statements that involve risks and uncertainties,
including, without limitation, risks inherent in the development and
commercialization of potential products, uncertainty of clinical trial results
or regulatory approvals or clearances, need for future capital, dependence upon
collaborators and maintenance of our intellectual property rights. Actual
results may differ materially from the results anticipated in these
forward-looking statements. Additional information on potential factors that
could affect our results and other risks and uncertainties will be detailed
from time to time in GenSpera's periodic reports filed with the Securities and
Exchange Commission.
Contact:
Company:
Craig Dionne, PhD, CEO
GenSpera, Inc.
+1-210-479-8112
Craig Dionne, PhD, CEO
GenSpera, Inc.
+1-210-479-8112
Media: Dawn Van Zant
800-665-0411
800-665-0411
Disclaimer/Disclosure: Investorideas.com
newswire is a third party publisher of news and research as well as creates
original content as a news source. Original content created by investorideas is
protected by copyright laws other than syndication rights. Investorideas is a
news source on Google news and Linkedintoday plus hundreds of syndication
partners. Our site does not make recommendations for purchases or sale of
stocks or products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investment involves
risk and possible loss of investment. This site is currently compensated by
featured companies, news submissions, content marketing and online advertising.
Contact each company directly for press release questions. Disclosure is posted
on each release if required but otherwise the news was not compensated for and
is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure:
Genspera (GNSZ) has engaged Investor Ideas for PR and news publication
effective June 18,2014 (compensation of five thousand per month and average of
eleven thousand five hundred 144 shares per month)
BC
Residents and Investor Disclaimer : Effective September 15 2008 - all BC
investors should review all OTC and Pink sheet listed companies for adherence
in new disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors
must adhere to regulations of each country.
Become an
Investorideas.com Member and access our 14 online stock directories 24/7
-mining stocks, oil and gas stocks and more...
No comments:
Post a Comment